Address: Guilinyang Industrial Development Zone, Haikou, Hainan, China
Tel: 0898-65710069
Hainan Dongfang Dahui Starch Products Co., Ltd. is a national key leading enterprise in agricultural industry which owned the state’s financial investment, integrating cassava cultivation, production , deep-processing, etc, and owning 6 production lines to produce chemical modified starch, drying modified starch, pre-gelatinized modified starch, glutinous rice starch, etc, which supply series of high-quality cassava starch and modified starch products, widely used in the fields of food, paper, textile, feed, construction materials, petroleum, chemical industry, etc.. It has passed Certification of ISO9001-2008 Quality Management System, and HACCP-EC-01 Certification of Food Safety Management System. In 2006, it is honored as National Agricultural Products Processing Demonstration Enterprise by China Agricultural Department. Meanwhile, it is the only manufacture of organic cassava starch in China, which passed the organic certification of Canada, USDA, IFOAM and OFDC organization.
Food Series
Modified starch glue prime
Feed Series
Chemical Building Materials Series
Modified starch glue prime
Petroleum chemicals Series
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
